Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
09 Oktober 2023 - 2:00PM
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company
developing a new generation of oral integrin therapies for the
treatment of serious chronic diseases, today announced it will host
a webcast and conference call to discuss the complete results from
the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with
moderate to severe ulcerative colitis. The positive topline
results from EMERALD-1 were reported in April of this year and
the full data set will be presented at the upcoming UEG Week 2023.
The webcast and call will be held at 7:45 AM
Eastern Time on October 12, 2023.
A live webcast of the call will be available via
this link or on the Investors section of Morphic’s website, at
www.morphictx.com. An archived replay will be available on the
company’s website following the conference call. To join the
question-and-answer queue on the live conference call, please click
here to register and receive a personalized dial in number.
About MORF-057 Morphic is
developing MORF-057 as a selective, oral small molecule inhibitor
of the α4β7 integrin for patients with inflammatory bowel disease
(IBD). α4β7 has been clinically validated as a target for the
treatment of IBD by the success of the approved injectable antibody
therapeutic vedolizumab. MORF-057, like vedolizumab, is designed to
block the interactions between α4β7 on the surface of lymphocytes
and the mucosal endothelial cell ligand MAdCAM-1, substantially
reducing lymphocyte migration from the bloodstream into intestinal
mucosal tissues and avoiding inflammation that is associated with
IBD.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a
portfolio of oral integrin therapies for the treatment of serious
chronic diseases, including autoimmune, cardiovascular, and
metabolic diseases, fibrosis, and cancer. Morphic is also advancing
its pipeline and discovery activities in collaboration with
Schrödinger using its proprietary MInT technology platform which
leverages the Company’s unique understanding of integrin structure
and biology. For more information, visit www.morphictx.com.
Contact Morphic Therapeutic Chris Erdman
chris.erdman@morphictx.com 617.686.1718
Morphic (NASDAQ:MORF)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Morphic (NASDAQ:MORF)
Historical Stock Chart
Von Sep 2023 bis Sep 2024